Extracellular Vesicles Infusion Treatment for Mild-to-Moderate COVID-19

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

December 7, 2022

Primary Completion Date

March 7, 2023

Study Completion Date

March 7, 2023

Conditions
COVID-19
Interventions
DRUG

ExoFlo

Patients will be randomized to one of three infusions: (1) Normal Saline 100 mL, (2) Normal saline 90 mL and ExoFlo 10 mL, which is 7x1011 EVs, and (3) Normal saline 85 mL and ExoFlo 15 mL, which is 10.5x1011 EVs. The study intervention will only be dosed on day=1

Sponsors
All Listed Sponsors
lead

Direct Biologics, LLC

INDUSTRY